The review concluded that BTX-A may be a treatment option for urinary incontinence in patients with MS or SCI; adverse events limited the applicability of Capsaicin. The ideal patient, dose and interval of use, and the long-term effectiveness were uncertain. Although the authors' conclusions reflected the evidence presented, methodological limitations made the reliability of the conclusions unclear.
Study selection
Randomised controlled trials (RCTs) in adults with urinary incontinence secondary to SCI or MS were eligible for inclusion. Non randomised trials of BTX-A were also eligible. This abstract would concentrate on the analysis of RCTs due to the classification of a systematic review as a non-randomised study. Patients in the included trials had either SCI (43 per cent) or MS (52per cent) and rarely other spinal disorders (5 per cent). The interventions were Botulinum toxin-A (BTX-A) injected into the detrussor muscle of the urinary bladder, or intravesical instillation of Capsaicin or Resiniferatoxin (RTX). Outcomes of interest included changes in the number of episodes of urinary incontinence and adverse events. The mean or median age of trial participants ranged from 35.3 to 47 years. The duration of the condition at the time of intervention ranged from one to 17.5 years. The average daily urinary incontinence episodes at the baseline ranged from two to 5.5. Study duration ranged from four weeks to 18 months, with five studies of at least 90 days duration.
The authors stated neither how many reviewers screened studies for relevance nor how any discrepancies were resolved.
Assessment of study quality
Validity was assessed based on the quality of concealment of treatment allocation, blinding of interventions, intention to treat analysis and loss of follow up. The authors stated neither how many reviewers performed the assessment nor how any discrepancies were resolved.
Data extraction
Mean differences for continuous data and relative risks (RR) for dichotomous data were calculated, along with their 95% confidence intervals (CI). The authors stated neither how the data were extracted for the review nor how many reviewers performed the data extraction.
Methods of synthesis
The pooled RR or weighted mean difference (WMD) and their 95% CI were calculated using a fixed-effect model, when heterogeneity was not observed. Heterogeneity was assessed using the X 2 and I 2 tests.
BTX-A significantly reduced the number of daily episodes of incontinence at 24 weeks when compared to placebo (-1.1 episodes for BTX-A and -0.1 episodes for placebo; p=0.019; one RCT, n=59) . When compared to RTX, BTX-A significantly reduced the number of incontinent episodes (WMD -1.30; 95% CI: -2.09, -0.51; one RCT; n=25). There was no significant difference in the incidence of adverse events between groups in either trial.
Three out of four trials (n=77) showed that Capsaicin significantly reduced the episodes of incontinence per day at 30 days compared to placebo; two trials were pooled (WMD -3.8; 95% CI: -4.7, -2.9, n=32). One trial showed Capsaicin to reduce the number of incontinence pads per day compared to placebo (four versus 10; p=0.02). Capsaicin therapy was associated with increased risk of pelvic pain (RR 2.07, 95% CI: 1.04, 4.14; three RCTs) and facial flush (RR 2.53, 95% CI: 1.01, 6.31; three RCTs).
When Capsaicin was compared to RTX (two RCTs; n=63). One trial reported a decrease in daily urinary incontinence episodes for both agents, with no significant difference between drugs (number of episodes ranged from 0 to 7 for RTX and 0 to 22 for Capsaicin at 90 days). The other trial reported a reduction in urinary leakages with RTX only (5/10 receiving RTX and 9/10 receiving Capsaicin were using pads at 60 days). The incidence of pelvic pain was significantly greater in the Capsaicin group compared to RTX (RR 3.86; 95% CI: 1.50, 9.92, two RCTs).
When RTX was compared to placebo, there was no significant difference in daily incontinence episodes (two RCTs; n=63). Pelvic pain (39.3 per cent) and autonomic dysreflexia (14.2 per cent) were reported with RTX; no adverse events were reported with placebo.
